Literature DB >> 22820555

Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain.

Linda Scoriels1, Peter B Jones, Barbara J Sahakian.   

Abstract

Modafinil is a central nervous system wake promoting agent used for the treatment of excessive daytime sleeping. Its vigilance promoting properties and low abuse potential has intrigued the scientific community and has led to use it as a cognitive enhancer, before its neural functions were understood. Here, we review the effects of modafinil in human cognition and emotion and its specific actions on symptoms in patients with schizophrenia and whether these are consistently effective throughout the literature. We also performed a systematic review on the effects of modafinil on neurotransmitter signalling in different areas of the brain in order to better understand the neuromechanisms of its cognitive and emotional enhancing properties. A review of its effects in schizophrenia suggests that modafinil facilitates cognitive functions, with pro-mnemonic effects and problem solving improvements. Emotional processing also appears to be enhanced by the drug, although to date there are only a limited number of studies. The systematic review on the neurochemical modulation of the modafinil suggests that its mnemonic enhancing properties might be the result of glutamatergic and dopaminergic increased neuronal activation in the hippocampus and in the prefrontal cortex respectively. Other neurotransmitters were also activated by modafinil in various limbic brain areas, suggesting that the drug acts on these brain regions to influence emotional responses. These reviews seek to delineate the neuronal mechanisms by which modafinil affects cognitive and emotional function. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820555     DOI: 10.1016/j.neuropharm.2012.07.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  27 in total

1.  Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens.

Authors:  Takuya Funayama; Yumiko Ikeda; Amane Tateno; Hidehiko Takahashi; Yoshiro Okubo; Haruhisa Fukayama; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Innovative methods for improving cognition, motivation and wellbeing in schizophrenia.

Authors:  Barbara J Sahakian; George Savulich
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 3.  Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.

Authors:  L-S Camilla d'Angelo; George Savulich; Barbara J Sahakian
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

4.  Modafinil enhances cognitive, but not emotional conflict processing via enhanced inferior frontal gyrus activation and its communication with the dorsomedial prefrontal cortex.

Authors:  Jialin Li; Xi Yang; Feng Zhou; Congcong Liu; Zhenyu Wei; Fei Xin; Bianca Daumann; Jörg Daumann; Keith M Kendrick; Benjamin Becker
Journal:  Neuropsychopharmacology       Date:  2020-01-29       Impact factor: 7.853

5.  Modafinil in schizophrenia: is the risk worth taking?

Authors:  Daniel Neto; Carla Spínola; Joaquim Gago
Journal:  BMJ Case Rep       Date:  2017-06-05

6.  Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study.

Authors:  Christopher Rohde; Christoffer Polcwiartek; Marton Asztalos; Jimmi Nielsen
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 7.  The hypocretin system and psychiatric disorders.

Authors:  Fabio Pizza; Michele Magnani; Camilla Indrio; Giuseppe Plazzi
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

8.  The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial.

Authors:  Florien W Boele; Linda Douw; Marjolein de Groot; Hinke F van Thuijl; Wilmy Cleijne; Jan J Heimans; Martin J B Taphoorn; Jaap C Reijneveld; Martin Klein
Journal:  Neuro Oncol       Date:  2013-08-07       Impact factor: 12.300

9.  Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice.

Authors:  Betina González; Mariana Raineri; Jean Lud Cadet; Edgar García-Rill; Francisco J Urbano; Veronica Bisagno
Journal:  Neuropharmacology       Date:  2014-02-12       Impact factor: 5.250

Review 10.  Modafinil for people with schizophrenia or related disorders.

Authors:  Javier Ortiz-Orendain; Sergio A Covarrubias-Castillo; Alan Omar Vazquez-Alvarez; Santiago Castiello-de Obeso; Gustavo E Arias Quiñones; Maya Seegers; Luis Enrique Colunga-Lozano
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.